依达拉奉保护创伤性休克患者肾功能的临床观察

王斌; 王鹏; 杨义琴; 祝茂盛; 马伟

doi:10.13201/j.issn.1009-5918.2012.04.026

依达拉奉保护创伤性休克患者肾功能的临床观察

- 重庆市长寿区人民医院急救重症部(重庆, 401220)

详细信息

通讯作者: 王斌,E-mail:wb19630827@163.com

中图分类号: R605.971

收稿日期: 2011-10-25

The clinical investigation of protective effects of Edaravone on kidney at traumatic shock

- Department of Emergency, the People's Hospital of Changshou District, Chongqing, 401220, China

More Information

Corresponding author: WANG Bin, E-mail: wb19630827@163.com

Received Date: 25 October 2011

摘要

摘要: 目的：探讨依达拉奉对创伤性休克患者肾脏功能的保护作用。方法：将83例创伤性休克随机分为依达拉奉治疗组（ED）（n=44）和常规治疗组（C）（n=39）；ED组在积极抗休克同时予以依达拉奉0.5 mg/kg静脉输入，C组予常规抗休克治疗。两组分别于入院时和休克稳定后6 h、12 h、24 h检测患者血尿素氮（BUN）、血清光抑素（CysC）、内生肌酐清除率（CCr）等指标进行对比分析。结果：ED组血液中BUN、CysC在休克纠正后6 h、12 h、24 h显著低于C组；内生肌酐清除率（CCr）明显高于C组（P<0.05）。结论：ED对创伤性休克后肾脏缺血再灌注损伤具有明显保护作用。
- 休克,创伤性 /
- 肾脏功能 /
- 依达拉奉
Abstract: Objective: To investigate the protective effect of Edaravone on kidney at traumatic shock.Method: Eighty-three cases of traumatic shock patients were randomly divided into Edaravone group (ED, n=44) and routine group (C, n=39). The patients of ED group were treated with anti-shock and Edaravone 0.5 mg/Kg. The patients of C group were only treated with routine anti-shock. Blood samples were obtained for determination of blood urea nitrogen (BUN), (CysC) and creatinine clearance rate (CCr) at 6 h, 12 h and 24 h after the corrected shock.Result: Compared with C group, the level of BUN and CysC of ED group was obviously lower at each times (P<0.05); the level CCr in ED group was obviously higher at each times (P<0.05).Conclusion: Edaravone can protect kidney function at traumatic shock.
- traumatic shock /
- renal function /
- Edaravone

HTML全文

参考文献(11)

[1]	LAMEIRE N,VAN BIESEN W,VANHOLDER R.Acute renal failure[J].Lancet,2005,365:417-430.
[2]	SULIKOWSKI T,DOMANSKI L.Effect of trimetazidine on oxidoreductase expression in rat kidney with ischemia-reperfusion injury[J].Arch Med Res,2008,39:456-462.
[3]	顾学兰.依达拉奉的临床研究及进展[J].世界临床药物,2004,11(25):696-699.
[4]	李检牛,杨友松.新型氧自由基清除剂依达拉奉的脑保护作用[J].国际神经病学神经外科杂志,2006,33(2):125-128.
[5]	TANIGUCHI M,UCHINAMI M,DOI K,et al.Edaravone reduce ischemia-reperfusion injury mediators in rat liver[J].J Surg Res,2007,137:69-74.
[6]	张珂,徐秋萍,黄海英.依达拉奉对大鼠肾缺血再灌注损伤的保护作用[J].浙江大学学报(医学版),2008,37(3):308-312.
[7]	江波涛,刘修恒,陈晖,等.依达拉奉对犬肾缺血再灌注损伤的保护作用[J].武汉大学学报(医学版),2010,31(3):309-312.
[8]	樊游掌,谢建军,苏怀庆,等.依达拉奉对大鼠移植肾缺血再灌注损伤急性期的影响及作用[J].中国临床医学,2010,17(2):98-100.
[9]	肖志梅.依达拉奉在日本接受更多安全警告[J].中国药师,2004,7(9):672-672.
[10]	ROUTLED P A,OMAHONYM S,WOODOUSE K W,et al.Adverse drug reactions in elderly patients[J].Br J Clin Phamacol,2004,13:188-192.
[11]	王淑洁,张建华,李俊英,等.依达拉奉不良反应的文献分析[J].实用药物与临床,2009,12(6):446-447.